Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent, Branko Cuglievan, Michael E Roth, Sairah Ahmed, Karen Albritton, Michelle A T Hildebrandt
{"title":"Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.","authors":"Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent, Branko Cuglievan, Michael E Roth, Sairah Ahmed, Karen Albritton, Michelle A T Hildebrandt","doi":"10.1080/10428194.2025.2499607","DOIUrl":null,"url":null,"abstract":"<p><p>Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12-44). Patients who reported fevers and night sweats had shorter TTT than those who did not (<i>p</i> = 0.016 and <i>p</i> = 0.017, respectively). TTT varied significantly by age group (<i>p</i> < 0.01), with adolescents (15-18 years) having nearly a 10-day shorter TTT (21.3 days) compared to a TTT of 30.2 and 31.2 days for emerging adults (19-25 years) and young adults (26-39 years), respectively. Delayed TTT was not associated with risk of death. The lack of association with survival may reflect the overall favorable survival experienced by AYA HL patients and is in line with that reported for HL across all age populations.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2499607","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12-44). Patients who reported fevers and night sweats had shorter TTT than those who did not (p = 0.016 and p = 0.017, respectively). TTT varied significantly by age group (p < 0.01), with adolescents (15-18 years) having nearly a 10-day shorter TTT (21.3 days) compared to a TTT of 30.2 and 31.2 days for emerging adults (19-25 years) and young adults (26-39 years), respectively. Delayed TTT was not associated with risk of death. The lack of association with survival may reflect the overall favorable survival experienced by AYA HL patients and is in line with that reported for HL across all age populations.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
